Request Demo
Last update 31 Mar 2026
Sosimerasib
Last update 31 Mar 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 硫酸索美来昔, HBI-2438, HBI2438 + [5] |
Target |
Action inhibitors |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (25 Feb 2026), |
RegulationPriority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China) |
Login to view timeline
Related
9
Clinical Trials associated with SosimerasibNCT07242274
A Multicenter, Randomized, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of JMKX001899 Versus Docetaxel in Previously Treated Patients With KRAS G12C-Mutant Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06946927
A Phase Ib, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of JMKX001899 in Combination With Other Therapies in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation.
NCT06473948
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect of JMKX001899 on the QTc Interval in Healthy Subjects
100 Clinical Results associated with Sosimerasib
Login to view more data
100 Translational Medicine associated with Sosimerasib
Login to view more data
100 Patents (Medical) associated with Sosimerasib
Login to view more data
100 Deals associated with Sosimerasib
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| KRAS G12C mutant Non-small Cell Lung Cancer | China | 25 Feb 2026 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| KRAS G12C mutation Solid Tumors | Phase 2 | China | 12 May 2022 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 06 Jun 2025 | |
| Solid tumor | Phase 1 | - | 01 Apr 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Aug 2022 | |
| Colonic Cancer | Phase 1 | United States | 01 Aug 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | United States | 01 Aug 2022 | |
| Pancreatic Cancer | Phase 1 | United States | 01 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 145 | hnoaeqtvkh(uzikjbgwtw) = hmhmhqklkj obwxhtldeo (spyhrgzguc, 44.0 - 60.8) View more | Positive | 30 May 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free